Apigenin has been established as a PPARγ ligand; moreover, Escande et al. have shown that apigenin is a NAD+ ase CD38 inhibitor, and Nicholas et al. found apigenin to be a modulator of NF-kB in macrophages which improves metabolic syndrome [109,157,165,179]. This evidence concerns the gene PPARG and metabolic syndrome.